POLE and endometrial cancer: Notably, the amino acid mutation p.Ala456Pro (p.A456P; c.1366G>C) identified on exon 14, is situated in the exonuclease domain and has been suggested as a recurrent somatic aberration and identified as a pathogenic POLE hotspot mutation for endometrial cancer (37, 38).